Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-528-4 | CAS number: 122-20-3
Carcinogenicity
Administrative data
Description of key information
In a limited 104-week dietary study, no histological evidence of increased liver foci was found in male rats in response to dietary administration of 2% TIPA. In addition, the substance is not mutagenic and no hyperplasia and/or pre-neoplastic lesions were observed in the oral semichronic repeated dose toxicity study.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
No further details.
Justification for classification or non-classification
Based on the results of a 104-week dietary study with 2% TIPA, the absence of hyperplasia and/or pre-neoplastic in the oral semichronic repeated dose toxicity study and the negative in vitro and in vivo genotoxicity studies, TIPA is considered to be non-carcinogenic; therefore classification according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008 is not warranted.
Additional information
A limited 104-week dietary study with 0 or 2% TIPA in the feed was conducted using 21 male Wistar rats per dose (Yamamoto et al., 1989). Additional groups (28 animals/dose) were co-treated with TIPA and 0.15% or 0.3% sodium nitrite (NaNO2). No preneoplastic GST-P-positive foci were observed in the liver of TIPA or TIPA and NaNO2 treated rats.
Furthermore, the substance is not mutagenic and no hyperplasia and/or pre-neoplastic lesions were observed in the oral semichronic repeated dose toxicity study with TIPA.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
